Transcend Capital Advisors LLC Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)


Transcend Capital Advisors LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating ) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,584 shares of the medical equipment provider’s stock, valued at approximately $203,000.

Other hedge funds have also modified their holdings of the company. Amplius Wealth Advisors LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $26,000. Widmann Financial Services Inc. acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $28,000. FSB Premier Wealth Management Inc. acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $33,000. US Asset Management LLC acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at $33,000. Finally, Paragon Capital Management Ltd acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $34,000. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have commented on ZBH. Goldman Sachs Group cut their target price on Zimmer Biomet from $179.00 to $155.00 and set a “buy” rating on the stock in a report on Monday, March 21st. Truist Financial decreased their price objective on Zimmer Biomet from $142.00 to $131.00 in a research report on Wednesday, May 4th. StockNews.com lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Citigroup dropped their price objective on Zimmer Biomet from $135.00 to $125.00 and set a “no” rating for the company in a research report on Tuesday, May 17th. Finally, Needham & Company LLC lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Friday, May 27th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the company’s stock. Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $141.00, according to MarketBeat.

Shares of ZBH stock opened at $107.27 on Tuesday. The company has a market cap of $22.48 billion, a P/E ratio of 104.15, a price-to-earnings-growth ratio of 2.57 and a beta of 1.17. The company has a debt-to-equity ratio of 0.44, a quick earnings ratio of 0.89, and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. it has a 52-week low of $101.22 and a 52-week high of $165.40. The business has a 50 day simple moving average of $114.81 and a two hundred day simple moving average of $120.85.

Zimmer Biomet (NYSE:ZBH – Get Rating ) last announced its earnings results on Tuesday, May 3rd. The medical equipment provider reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.21. Zimmer Biomet had a return on equity of 12.23% and a net margin of 2.85%. The firm had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the previous year, the business earned $1.71 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will report 6.72 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Monday, June 27th will be given a $0.24 dividend. The ex-dividend date is Friday, June 24th. This represents an annualized dividend of $0.96 and a dividend yield of 0.89%. Zimmer Biomet’s payout ratio is currently 93.20%.

Zimmer Biomet Company Profile (Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, Middle East, Africa and Asia Pacific. The company designs, manufactures and markets orthopedic reconstructive products, such as knee and hip products; KIT

Selected articles

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE: ZBH – Get Rating ).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)



Get Zimmer Biomet Daily news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.